ScoreWhy is Venmax Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 200.30% and Operating profit at 10.45% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 1.16 times
2
Flat results in Mar 26
3
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 01-Jun-26 and has generated -6.91% returns since then
- Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
4
With ROE of 4.6, it has a Very Expensive valuation with a 5.4 Price to Book Value
- Over the past year, while the stock has generated a return of -25.53%, its profits have risen by 26% ; the PEG ratio of the company is 0.1
5
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 0.84% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -25.53% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Venmax Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Venmax Drugs
-25.53%
-0.47
54.33%
Sensex
-4.95%
-0.37
13.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
200.30%
EBIT Growth (5y)
10.45%
EBIT to Interest (avg)
-0.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0.28
Tax Ratio
13.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.73%
ROE (avg)
0.09%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
119
Industry P/E
34
Price to Book Value
5.40
EV to EBIT
21.25
EV to EBITDA
21.25
EV to Capital Employed
11.07
EV to Sales
2.65
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
-52.08%
ROE (Latest)
4.56%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
PAT(9M)
Higher at Rs 0.16 Cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Venmax Drugs
Profit After Tax (PAT) - Nine Monthly
Higher at Rs 0.16 Cr
than preceding 12 month period ended Mar 2026 of Rs 0.02 crMOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
PAT (Rs Cr)
